[pavulon]

ASCO 2024: New ultra-sensitive blood test predicts recurrence of breast cancer, months or even years before relapse

Molecular residual disease was detected in all 11 patients who relapsed. The median lead time to clinical relapse in this group of patients was 15 months, an increase of over three months, compared with current tests in all types of breast cancer. The longest lead time to clinical relapse was 41 months.

None of the 60 women in whom ctDNA remained undetected, relapsed throughout the follow-up period. Three patients had ctDNA detected in follow-up but had not relapsed by the end of the study – the researchers didn’t have samples to analyse beyond the study follow-up period. Median survival for ctDNA detected patients was 62 months and not reached for the patients in whom ctDNA was undetected.

https://www.icr.ac.uk/news-archive/asco-2024-new-ultra-sensitive-blood-test-predicts-recurrence-of-breast-cancer-months-or-even-years-before-relapse#:~:text=01,treatment%20for%20early%20breas t%20cancer.